Silo Pharma Announces Agreement With Sever Pharma Solutions To Scale-Up Production And Continue Testing Of SP-26 Dissolvable Ketamine-Based Implant Targeting Chronic Pain And Fibromyalgia
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma has entered into an agreement with Sever Pharma Solutions to scale up production and continue testing of its SP-26 dissolvable ketamine-based implant, which targets chronic pain and fibromyalgia.
August 14, 2024 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silo Pharma has partnered with Sever Pharma Solutions to scale up production and continue testing of its SP-26 dissolvable ketamine-based implant, aimed at treating chronic pain and fibromyalgia.
The partnership with Sever Pharma Solutions is likely to accelerate the development and commercialization of SP-26, potentially leading to increased investor confidence and a positive short-term impact on Silo Pharma's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100